These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38870067)

  • 1. Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection.
    Wang P; Liu S; He X; Miao W; Sun T; Yang J
    J Antimicrob Chemother; 2024 Aug; 79(8):1969-1973. PubMed ID: 38870067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study.
    Hu Y; Li D; Zhang G; Dai Y; Chen M; Jiang H; Cui W
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):875-884. PubMed ID: 38443737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR
    Pan S; Huang X; Wang Y; Li L; Zhao C; Yao Z; Cui W; Zhang G
    Antimicrob Resist Infect Control; 2018; 7():8. PubMed ID: 29387342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia.
    Ding P; Li H; Nan Y; Liu C; Wang G; Cai H; Yu W
    Int J Antimicrob Agents; 2024 Oct; 64(4):107293. PubMed ID: 39094752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
    Ni M; Zhao L; Zhang WJ; Ma JW; Zhang GY; Cui DM; Wang K; Fei YB; Gao L; Shen FM
    Int J Antimicrob Agents; 2021 Mar; 57(3):106281. PubMed ID: 33465459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of risk factors and outcomes of cerebrospinal fluid shunt infections caused by carbapenem-resistant gram-negative bacteria in children: a retrospective cohort.
    Guner Ozenen G; Sahbudak Bal Z; Bolat E; Umit Z; Bilen NM; Yildirim Arslan S; Turhan T; Cilli F; Kurugol Z
    J Neurosurg Pediatr; 2024 Jun; 33(6):591-601. PubMed ID: 38489813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
    Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K
    Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB.
    Liu D; Jie F; Ding Y; Qu H; Chen D; Huang J
    J Infect Dev Ctries; 2024 Jul; 18(7):1050-1057. PubMed ID: 39078788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of polymyxin B versus colistin for treating patients with carbapenem-resistant gram-negative bacterial infections.
    Wang Y; Yu L; Zhu J; Liang G; Liu J; Zheng Y; Zhao Y; Yu Z
    Sci Rep; 2024 Oct; 14(1):23635. PubMed ID: 39384871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Teng CB; Koh PT; Lye DC; Ang BS
    Int J Antimicrob Agents; 2008 Jan; 31(1):80-2. PubMed ID: 17920246
    [No Abstract]   [Full Text] [Related]  

  • 15. Polymyxin B adjuvants against polymyxin B- and carbapenem-resistant Gram-negative bacteria.
    Salvaterra Pasquini JP; Queiroz PA; Rodrigues do Amaral PH; da Silva TC; Souza Bonfim Mendonça P; Vandresen F; Carvalho Ceolis JP; de Lima Scodro RB; Caleffi-Ferracioli KR; Cardoso RF; Dias Siqueira VL
    Future Microbiol; 2024; 19(17):1445-1454. PubMed ID: 39258398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
    Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
    Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
    Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
    Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
    Liu S; Wu Y; Qi S; Shao H; Feng M; Xing L; Liu H; Gao Y; Zhu Z; Zhang S; Du Y; Lu Y; Yang J; Chen P; Sun T
    Crit Care; 2023 Jun; 27(1):232. PubMed ID: 37312218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
    Ting SW; Lee CH; Liu JW
    J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.